Related Experiment Videos
Uremic ultrafiltrate inhibits platelet-activating factor synthesis
M L Wratten1, C Tetta, R De Smet
1Department of Clinical Research, Bellco SpA, Mirandola, Italy.
Blood Purification
|August 18, 1999
Summary
Uremic toxins in chronic kidney disease patients inhibit platelet-activating factor (PAF) synthesis by leukocytes. This inhibition is linked to reduced activity of key enzymes involved in PAF production.
Area of Science:
- Nephrology
- Immunology
- Biochemistry
Background:
- Uremic toxins may negatively impact phagocytic leukocytes in chronic renal failure.
- Platelet-activating factor (PAF) is a key inflammatory mediator produced by leukocytes.
Purpose of the Study:
- To investigate the effect of uremic ultrafiltrate on PAF synthesis in leukocytes.
- To identify specific uremic toxins responsible for inhibiting PAF production.
Main Methods:
- Leukocytes were incubated with normal or uremic ultrafiltrate and stimulated with yeast spores.
- PAF synthesis was quantified, and the activity of PAF synthesis enzymes (PLA2, acetyltransferase) was measured.
- Ultrafiltrate was fractionated using HPLC, and specific compounds were tested.
Main Results:
- Uremic ultrafiltrate significantly inhibited PAF synthesis compared to normal ultrafiltrate.
- Hydrophobic fractions of uremic ultrafiltrate, including phenol and p-cresol, showed strong PAF inhibition.
- Activities of phospholipase A2 (PLA2) and acetyltransferase were reduced by uremic ultrafiltrate.
Conclusions:
- Uremic ultrafiltrate inhibits leukocyte PAF synthesis.
- This inhibition is associated with decreased activity of PLA2 and acetyltransferase, crucial for PAF production.